Trial Profile
Phase I Trial Of Intrahepatic Infusion Of 2nd Generation Designer T Cells For Cea-Expressing Liver Metastases
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti CEA CAR T cell therapy Sorrento Therapeutics (Primary)
- Indications Liver metastases
- Focus Adverse reactions
- 10 Apr 2017 New trial record
- 03 Apr 2017 Results (n=1) published in the Sorrento Therapeutics Media Release